Anti-DRAK2 (CT) Antibody
Catalog No.: 2149
Size: 100ug IgG in PBS, pH 7.4, purified by immunoaffinity chromatography.
Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis have been identified and designated DRAK1 and DRAK2 for DAP kinase–related apoptosis-inducing protein kinases. DRAKs contain an N-terminal kinase domain and a C- terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases which mediate apoptosis through their catalytic activities. DRAK2 is located in cell nuclei, and the mRNA for DRAK2 is ubiquitously expessed in human tissues.
Antigen: Peptide corresponding to aa 351-365 of human DRAK2 (accession no. AB011421).
Host Species: Rabbit
Preservatives: 0.02% sodium azide.
This antibody recognizes human DRAK2 (45kDa). No cross-reactivity with DRAK1, DAP or ZIP kinases.
Immunoblotting: use at 1ug/ml.
Immunocytochemistry: use at 10ug/ml.
Positive control: Whole cell lysate from Jurkat or Raji cells.
These are recommended concentrations. Enduser should determine optimal concentrations or their applications.
Dilute in PBS or medium which is identical to that used in the assay system.
STORAGE AND STABILITY
This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.
For in vitro investigational use only. Not for use in therapeutic or diagnostic procedures.